Renal Cancer
New clinical data presented at the 2026 International Kidney Cancer Symposium (IKCS) Europe supports the potential of next-generation FTI darlifarnib, alone and in combination with cabozantinib, to overcome resistance and resensitize tumors to VEGFR TKI therapy in clear cell renal cell carcinoma (ccRCC)
See who the oncology community selected as the rising stars of 2026!
The 2026 ASCO Genitourinary Cancers Symposium showcased pivotal advances across renal, prostate and bladder cancers. Key late-breaking trials across kidney, prostate and bladder cancer highlighted promising combinations, novel targeted therapies and innovative radioligand approaches, demonstrating improved disease control, progression-free survival and ...
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
Fresh data from the ESMO 2025 Congress reveal major shifts in prostate and kidney cancer treatment. From radioligand therapy entering first-line prostate cancer to the first targeted AKT strategy in PTEN-deficient disease, and new benchmarks in RCC with LenCabo and RAMPART, the landscape is rapidly evolving.
The first head-to-head trial comparing standard second-line treatments for metastatic clear cell renal cell carcinoma has revealed a striking result: lenvatinib plus everolimus cut the risk of disease progression by nearly half compared with cabozantinib. In this interview, Dr Andrew W. Hahn (MD Anderson Cancer Center) discusses how the LenCabo trial could reshape post-immunotherapy care.
This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.
Dr. Pooja Ghatalia, an Associate Professor at Fox Chase Cancer Center, specializes in genitourinary oncology, focusing on kidney and bladder cancers. With expertise in immunotherapy and biomarker development, she combines cutting-edge research with compassionate care. Inspired by exceptional mentors, she advocates for persistence, curiosity, and patient-centered oncology, shaping future oncologists.
We’re looking forward to the ESMO Congress 2024 which is taking place in Madrid between 13- 17 September, 2024. Promising attendees an opportunity to explore the latest technologies, treatments, and products in the field of oncology, we are excited to provide independent, ...
Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘...
We joined Lorenza Rimassa (Humanitas Research Hospital-IRCCS) at ESMO 2019 to discuss the Phase III COSMIC-312 study (NCT03755791) of cabozantinib plus atezolizumab versus sorafenib in patients with advanced hepatocellular carcinoma. Questions 1. What are the limitations of current first-line treatment strategies for ...
Despite significant advances in diagnosis and treatment, renal cell carcinoma (RCC) remains one of the most lethal cancers. Worldwide, it is the 6th most commonly diagnosed malignancy in men and the 10th in women, and accounted for 5% and 3% of all ...
At the ASCO 2019 annual meeting, James Brugarolas discusses sarcomatoid renal cell carcinoma, the current challenges and the advances that are defining a new treatment paradigm. Questions 1. What is sarcomatoid renal cell carcinoma (RCC) and what is its prognosis? (0:04) 2. What are ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
